Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session 2: GU tumours, non-prostate

1736MO - Pure or mixed basal/squamous tumours present decreased outcomes after neoadjuvant chemotherapy in the GETUG-AFU V05 VESPER trial


12 Sep 2022


Mini Oral session 2: GU tumours, non-prostate


Translational Research;  Therapy

Tumour Site

Urothelial Cancer


Clarice Groeneveld


Annals of Oncology (2022) 33 (suppl_7): S785-S807. 10.1016/annonc/annonc1080


C.D.S. Groeneveld1, V. Harter2, S. Culine3, C. Krucker1, V. Dixon1, A. de Reynies4, C. PFISTER5, F. Radvanyi1, Y. Allory1

Author affiliations

  • 1 Umr144, Institut Curie, 75005 - Paris/FR
  • 2 North-west Canceropole Data Center, François Baclesse Comprehensive Cancer Center, 14076 - Caen/FR
  • 3 Medical Oncology Department, Hopital Saint Louis AP-HP, 75010 - Paris/FR
  • 4 Crc Cordeliers Meppot, Université de Paris, 75006 - Paris/FR
  • 5 Urology Department, Hopital Charles-Nicolle - CHU de Rouen, 76031 - Rouen/FR


Login to access the resources on OncologyPRO.

Abstract 1736MO


Molecular subtypes of urothelial carcinoma (UC) may impact the outcomes after neoadjuvant chemotherapy in muscle invasive bladder cancer (MIBC). Previous studies reported contradictory results in this setting. Here, we assessed pathological response and 3-year (yr) progression free survival (PFS) according to the consensus molecular subtypes for patients in the French prospective Vesper clinical trial (NCT01812369).


493 patients received dose-dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin (dd-MVAC) or Gemcitabine and Cisplatin (GC) after randomization in the VESPER trial. This ancillary study was restricted to patients treated in neoadjuvant setting. We performed 3’ mRNA sequencing on TURB FFPE tissue, taking multiple samples when morphology and/or multiplexed GATA3 Cytokeratin 5/6 TUBB2a immunostaining highlighted distinct patterns. Consensus molecular subtype was then determined for each area from their transcriptomic profile.


Out of 296 cases, 97 presented intra-tumor immunostaining heterogeneity. For 251 cases, one single molecular subtype was detected within the tumor, including 37 luminal papillary, 60 luminal unstable, 17 luminal non specified, 53 stroma-rich, 81 basal/squamous and 3 neuroendocrine-like. 45 cases were mixed including 2 or more molecular subtypes (27 with basal/squamous component). Pathological response was not statistically different between pure molecular subtypes, but was decreased for the mixed cases (OR=0.43, 95% CI 0.19-0.96, p=0.040). Compared to luminal and stroma-rich subtypes, 3yr PFS was significantly decreased when basal/squamous subtype was detected, either pure or admixed with another molecular type (HR=2.16, 95% CI 1.46-3.20, p<1e-3). Lymphovascular invasion was also found to be a significant risk factor for 3yr PFS (HR=1.91, 95% CI 1.29-2.83, p=0.001), independently from molecular subtype.


In the VESPER trial, the basal/squamous molecular subtype (pure or mixed) is associated with a decreased 3yr PFS after neoadjuvant chemotherapy in comparison with other subtypes. These results suggest the need to develop and validate new therapeutic strategies.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

The authors.


Institut National du Cancer (INCa).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.